Read more

July 05, 2023
1 min read
Save

Top in endocrinology: Early vs. late time-restricted eating; novel type 1 diabetes therapy

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

During a debate at the American Diabetes Association Scientific Sessions, one expert said that eating earlier in the day may yield more cardiometabolic benefit for adults than eating later.

Another expert said that some studies have shown the timing of time-restricted eating is not associated with differences in cardiometabolic metrics, and a later eating window may lead to better time-restricted eating adherence. It was the top story in endocrinology last week.

Healthy Foods in Container
During a debate at the American Diabetes Association Scientific Sessions, experts discussed research on the optimal timing of time-restricted eating. Image: Adobe Stock

The second top story was about the FDA’s approval of the first allogenic pancreatic islet cellular therapy for adults with type 1 diabetes. The approval was based on results of two single-arm trials in which 21 of 30 adults receiving the therapy achieved insulin independence for at least 1 year.

Read these and more top stories in endocrinology below:

Experts debate whether early or late time-restricted eating confers more benefits

Early time-restricted eating may confer more cardiometabolic benefits for adults than late time-restricted eating, but a later eating window may result in better adherence, according to two speakers. Read more.

FDA approves novel pancreatic islet cell therapy for adults with type 1 diabetes

The FDA approved an allogenic pancreatic islet cellular therapy for adults with type 1 diabetes who struggled to achieve their target HbA1c due to repeated episodes of severe hypoglycemia, according to an agency press release. Read more.

‘This raises the bar’: Phase 2 data show 24% weight loss with triple-agonist retatrutide

Adults with obesity who received the highest dose of a once-weekly injection of retatrutide lost an average of 24.2% of their body weight at 48 weeks compared with placebo, data from a phase 2 study show. Read more.

How to tailor care for LGBTQ+ people living with diabetes

Susan Weiner, MS, RDN, CDCES, FADCES, talks with Tessa Cushman, RDN, about addressing health inequities for people living with diabetes who identify as LGBTQ+. Read more.

Higher-dose oral semaglutide may be beneficial option for type 2 diabetes, obesity

Oral semaglutide 50 mg induces more than 15% weight loss in adults with obesity at 68 weeks and can reduce HbA1c by 2 percentage points at 52 weeks for those with type 2 diabetes, according to data from two phase 3 trials. Read more.